Annette S. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annette S. Kim has a total of 627 co-authors. Here are the top co-authors by number of shared publications:
Neal I. Lindeman
Department of Pathology, Weill Cornell Medicine, New York, NY
31 shared publications- Alice S. Mims
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
30 shared publications - Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
30 shared publications - Mark J. Levis
Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins University, Baltimore, MD
30 shared publications - Vincent T. Ho
Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA
30 shared publications - Yi-Bin Chen
Massachusetts General Hospital
30 shared publications
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2313
Dying to tell the diagnosis: apoptotic neutrophils in dyskeratosis congenita
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2313
Dying to tell the diagnosis: apoptotic neutrophils in dyskeratosis congenita
- Open Access
- 27 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2236-2243
Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing
Precise inter-laboratory quantitation of BCR::ABL1 RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory reproducibility in BCR::ABL1 quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of BCR::ABL1 results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; >5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption over 7 years (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SDs of reported BCR::ABL1 results (high-sample r = −0.73, p = 0.004; intermediate-sample r = −0.71, p = 0.022; low-sample r = −0.84, p = 0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with time-dependent improvement in inter-lab reproducibility, including reference gene selection ( ABL1 versus others), RQ-PCR reagent selection, assay type (FDA-approved, commercial, or laboratory-developed), or practice setting. IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in BCR::ABL1 quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.
- 27 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2236-2243
Open AccessImproved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing
Precise inter-laboratory quantitation of BCR::ABL1 RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory reproducibility in BCR::ABL1 quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of BCR::ABL1 results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; >5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption over 7 years (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SDs of reported BCR::ABL1 results (high-sample r = −0.73, p = 0.004; intermediate-sample r = −0.71, p = 0.022; low-sample r = −0.84, p = 0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with time-dependent improvement in inter-lab reproducibility, including reference gene selection ( ABL1 versus others), RQ-PCR reagent selection, assay type (FDA-approved, commercial, or laboratory-developed), or practice setting. IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in BCR::ABL1 quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.
- Top Cited Papers
- 18 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1468-1489
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE: To provide guidance on the use of circulating tumor DNA (ctDNA) testing in patients with solid tumors or lymphoma. METHODS: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2017 to February 2025. Guideline recommendations were based on consideration of the identified evidence. RESULTS: Fifty-four meta-analyses and 22 study reports were identified, including reports of seven randomized trials. RECOMMENDATIONS: ctDNA testing for tumor genetic alterations may be used in situations where: tumor tissue testing is challenging, not feasible, or tumor biopsy represents unacceptable risks to the patient; tumor tissue testing results may not be available within a clinically actionable time frame to determine appropriate management options; or a drug's regulatory approved indication allows for or requires ctDNA testing. If ctDNA testing results are negative, inconclusive, or inconsistent with the clinical scenario, tissue-based confirmation should be sought. Other than testing for genetic alterations, ctDNA testing may be offered if a specific, evidence-based action can be taken with the results or there is conflict or ambiguity with standard-of-care assessment that may be resolved by ctDNA testing. Fractional, percentage, or concentration-based measures of ctDNA or total cell-free DNA concentration are not recommended as a surrogate measure of disease. The panel recognizes this is a rapidly evolving field and guidelines are anticipated to change, bringing in tumor-type specific recommendations and incorporating more data on molecular residual disease settings. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .
- 18 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1468-1489
Top Cited PapersCirculating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE: To provide guidance on the use of circulating tumor DNA (ctDNA) testing in patients with solid tumors or lymphoma. METHODS: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2017 to February 2025. Guideline recommendations were based on consideration of the identified evidence. RESULTS: Fifty-four meta-analyses and 22 study reports were identified, including reports of seven randomized trials. RECOMMENDATIONS: ctDNA testing for tumor genetic alterations may be used in situations where: tumor tissue testing is challenging, not feasible, or tumor biopsy represents unacceptable risks to the patient; tumor tissue testing results may not be available within a clinically actionable time frame to determine appropriate management options; or a drug's regulatory approved indication allows for or requires ctDNA testing. If ctDNA testing results are negative, inconclusive, or inconsistent with the clinical scenario, tissue-based confirmation should be sought. Other than testing for genetic alterations, ctDNA testing may be offered if a specific, evidence-based action can be taken with the results or there is conflict or ambiguity with standard-of-care assessment that may be resolved by ctDNA testing. Fractional, percentage, or concentration-based measures of ctDNA or total cell-free DNA concentration are not recommended as a surrogate measure of disease. The panel recognizes this is a rapidly evolving field and guidelines are anticipated to change, bringing in tumor-type specific recommendations and incorporating more data on molecular residual disease settings. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (8) , 872-882
The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms
Clonal mature plasmacytoid dendritic cell proliferations (MPDCP) are a recently recognized entity in the WHO fifth edition, but their pathologic spectrum remains poorly characterized. Cases with extensive MPDCP in the bone marrow (BM) are rare and can exhibit overlapping features with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We compared clinicopathologic and genomic features of 11 patients with myeloid neoplasm-associated MPDCP to 5 patients with secondary BPDCN arising from clonally-related myeloid neoplasms. MPDCP exhibited variable degrees of BM involvement (5% to 50%) and architectural patterns, were uniformly positive for CD123, CD4, TCF4, and IRF8, variably positive for TCL1 (7/11), CD5 (7/11), and CD7 (2/11), and negative for SOX4, CD56, and TdT. MPDCP skin involvement was rare (1/11), with no CNS involvement. MPDCP heralded myeloid disease progression in a subset of patients, with increased blasts or progression to AML (4/11). In contrast, secondary BPDCN was uniformly positive for SOX4 and TCL1, with frequent CD56 (4/5) and subset/weak TdT (3/4). All BPDCN patients had characteristic skin lesions, and a subset with CNS involvement (2/5). The underlying myeloid neoplasms associated with MPDCP or BPDCN were enriched in TET2 , SRSF2 , ASXL1 , RUNX1 , and RAS pathway mutations. While karyotypic abnormalities were uncommon in MPDCP, all BPDCN showed chromosomal structural abnormalities and copy number variants, including deletions of 3p, 9p, and 12p. Our findings expand the histopathologic, immunophenotypic, and genetic characterization of MPDCP, and highlight pathologic features that distinguish it from BPDCN. Utilization of SOX4 immunohistochemistry, combined with careful clinical and molecular correlation, can aid in resolving these diagnostic challenges.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (8) , 872-882
The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms
Clonal mature plasmacytoid dendritic cell proliferations (MPDCP) are a recently recognized entity in the WHO fifth edition, but their pathologic spectrum remains poorly characterized. Cases with extensive MPDCP in the bone marrow (BM) are rare and can exhibit overlapping features with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We compared clinicopathologic and genomic features of 11 patients with myeloid neoplasm-associated MPDCP to 5 patients with secondary BPDCN arising from clonally-related myeloid neoplasms. MPDCP exhibited variable degrees of BM involvement (5% to 50%) and architectural patterns, were uniformly positive for CD123, CD4, TCF4, and IRF8, variably positive for TCL1 (7/11), CD5 (7/11), and CD7 (2/11), and negative for SOX4, CD56, and TdT. MPDCP skin involvement was rare (1/11), with no CNS involvement. MPDCP heralded myeloid disease progression in a subset of patients, with increased blasts or progression to AML (4/11). In contrast, secondary BPDCN was uniformly positive for SOX4 and TCL1, with frequent CD56 (4/5) and subset/weak TdT (3/4). All BPDCN patients had characteristic skin lesions, and a subset with CNS involvement (2/5). The underlying myeloid neoplasms associated with MPDCP or BPDCN were enriched in TET2 , SRSF2 , ASXL1 , RUNX1 , and RAS pathway mutations. While karyotypic abnormalities were uncommon in MPDCP, all BPDCN showed chromosomal structural abnormalities and copy number variants, including deletions of 3p, 9p, and 12p. Our findings expand the histopathologic, immunophenotypic, and genetic characterization of MPDCP, and highlight pathologic features that distinguish it from BPDCN. Utilization of SOX4 immunohistochemistry, combined with careful clinical and molecular correlation, can aid in resolving these diagnostic challenges.
- 18 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 751-766
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophosmin 1 (NPM1) mutations and nucleoporin 98 rearrangements, and represents an emerging opportunity for therapeutic intervention. Here, we report development and comprehensive evaluation of the activity of ziftomenib as an orally bioavailable, highly potent and selective small molecule inhibitor of the menin-KMT2A interaction. In leukemia cells and primary patient samples with the menin-KMT2A dependency, ziftomenib profoundly inhibited proliferation, reduced clonogenic potential and induced differentiation, which was associated with strong downregulation of the menin-KMT2A target genes, including MEIS1, HOXA9 and HOXB2. In xenografts and patient-derived xenograft models of KMT2A-rearranged leukemia, ziftomenib induced leukemia regression or reduced leukemia burden, accompanied by a pronounced reduction of the menin-KMT2A target genes. We next assessed ziftomenib against four MEN1 (gene encoding menin) mutants (T349M, M327I, G331R, G331D) associated with clinical resistance to another menin inhibitor revumenib. Ziftomenib retained anti-leukemic activity against T349M mutant cells and demonstrated low-nanomolar potency (GI50≤25 nM) against G331R cells, despite several-fold reduced potency relative to MEN1 wild-type cells, whereas M327I and G331D mutants were resistant. The crystal structures of ziftomenib in complex with menin wild-type, T349M or G331R mutants revealed a similar binding mode of ziftomenib to these menin variants, rationalizing potent inhibitory activity towards these mutants. Ziftomenib has recently received FDA approval for adult patients with NPM1-mutated acute myeloid leukemia and continues to be evaluated clinically in leukemias with NPM1 or KMT2A alterations, both as monotherapy and in combinations.
- 18 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (6) , 751-766
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
The protein-protein interaction between menin and KMT2A (histone lysine methyltransferase 2A) plays a critical role in acute leukemia with KMT2A rearrangements, nucleophosmin 1 (NPM1) mutations and nucleoporin 98 rearrangements, and represents an emerging opportunity for therapeutic intervention. Here, we report development and comprehensive evaluation of the activity of ziftomenib as an orally bioavailable, highly potent and selective small molecule inhibitor of the menin-KMT2A interaction. In leukemia cells and primary patient samples with the menin-KMT2A dependency, ziftomenib profoundly inhibited proliferation, reduced clonogenic potential and induced differentiation, which was associated with strong downregulation of the menin-KMT2A target genes, including MEIS1, HOXA9 and HOXB2. In xenografts and patient-derived xenograft models of KMT2A-rearranged leukemia, ziftomenib induced leukemia regression or reduced leukemia burden, accompanied by a pronounced reduction of the menin-KMT2A target genes. We next assessed ziftomenib against four MEN1 (gene encoding menin) mutants (T349M, M327I, G331R, G331D) associated with clinical resistance to another menin inhibitor revumenib. Ziftomenib retained anti-leukemic activity against T349M mutant cells and demonstrated low-nanomolar potency (GI50≤25 nM) against G331R cells, despite several-fold reduced potency relative to MEN1 wild-type cells, whereas M327I and G331D mutants were resistant. The crystal structures of ziftomenib in complex with menin wild-type, T349M or G331R mutants revealed a similar binding mode of ziftomenib to these menin variants, rationalizing potent inhibitory activity towards these mutants. Ziftomenib has recently received FDA approval for adult patients with NPM1-mutated acute myeloid leukemia and continues to be evaluated clinically in leukemias with NPM1 or KMT2A alterations, both as monotherapy and in combinations.
- Open Access
- 25 February 2026
- Published by Springer Nature in Research Square
Improved Inter-Lab Precision After CML International Scale Adoption: a 15-year history of BCR::ABL1 Proficiency Testing
Precise inter-laboratory quantitation of BCR::ABL1 RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory variability in BCR::ABL1 quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of BCR::ABL1 results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; >5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SD’s of reported BCR::ABL1 results (high sample r=-0.73, p=0.004; intermediate sample r=-0.71, p=0.022; low sample r=-0.84, p=0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with the time-dependent improvement in inter-lab reproducibility, including reference gene selection ( ABL1 versus others), RQ-PCR reagent selection, or assay type (FDA-cleared versus lab-developed). IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in BCR::ABL1 quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.
- 25 February 2026
- Published by Springer Nature in Research Square
Open AccessImproved Inter-Lab Precision After CML International Scale Adoption: a 15-year history of BCR::ABL1 Proficiency Testing
Precise inter-laboratory quantitation of BCR::ABL1 RNA is critical for effective chronic myeloid leukemia (CML) disease management. Although standardized reporting on the International Scale (IS) was specifically developed to improve inter-laboratory variability in BCR::ABL1 quantitation, the clinical impact of this reporting system has not been comprehensively assessed. We analyzed 15 years of BCR::ABL1 results (2009–2023) reported by over 200 clinical laboratories (6 annual samples; >5500 results) in a College of American Pathologists proficiency testing program. Inter-laboratory precision was evaluated by standard deviations (SD) for high, intermediate, and low-transcript samples. Early rapid IS adoption (8% of labs in 2009; 86% by 2015) was correlated with a progressive decrease in inter-lab SD’s of reported BCR::ABL1 results (high sample r=-0.73, p=0.004; intermediate sample r=-0.71, p=0.022; low sample r=-0.84, p=0.002). IS implementation exceeded 99% by 2019, as inter-lab SD’s reached their nadir value (~0.2). No other assessed variable correlated with the time-dependent improvement in inter-lab reproducibility, including reference gene selection ( ABL1 versus others), RQ-PCR reagent selection, or assay type (FDA-cleared versus lab-developed). IS-based reporting is thus likely the principal driver of enhanced inter-laboratory precision in BCR::ABL1 quantitation, validating the real-world clinical relevance of adopting robust standardization in clinical molecular diagnostics.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants